We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Today's Research Daily features new research reports on 16 major stocks, including Chevron (CVX - Free Report) , Glaxo (GSK - Free Report) and Aflac (AFL - Free Report) .
Chevron’s shares have gained more than 19% year-to-date. The analyst emphasizes that the company’s current oil and gas development project pipeline is among the best in the industry, boasting large, multi-year projects. Also, Chevron has been able to boost returns and remain competitive by embarking on aggressive cost reduction initiatives, exiting unprofitable markets and streamlining the organization.
Owing to these positives, the company has been able to report better-than-expected earnings in the third quarter. However, due to commodity price rout, Chevron’s upstream division has been able to extract less value for their products. (You can read the full research report on Chevron here.)
Glaxo’s shares have struggled recently. Glaxo’s third-quarter 2016 results were impressive with the company beating estimates on all fronts. The analyst likes Glaxo’s diversified base and presence in different geographical areas as well as its efforts to develop its pipeline.
The performance of new products as well as those acquired from Novartis is also encouraging. These should help support revenues and ease the impact of the loss of Advair sales. However, challenges remain in the form of increasing competition, genericization and pricing pressure, which will continue to impact the company’s performance. (You can read the full research report on Glaxo here.)
Aflac’s shares have increased by more than 8% year-to-date. Aflac’s third quarter earnings exceeded expectations and grew year over year. The analyst likes the way in which company is trying to differentiate itself from its rivals by paying claims in one day through a program named “One Day Pay.” Aflac’s strong capital position enables it to buy back shares and increase dividend payouts at regular intervals.
Efforts to increase agent productivity also will drive long-term growth. However, Aflac’s top line remains exposed to a challenging operating environment, primarily in Japan. (You can read the full research report on Aflac here.)
Confidential: Best Trades from Zacks Research Would you like to see a hand-picked "all-star" selection of investment ideas from the man who heads up Zacks' trading and investing services? Steve Reitmeister knows when key trades are about to be triggered and which of our experts has the hottest hand. He is now prepared to pass them along to you. From 220 Zacks Rank #1 Strong Buys, this Special tabs 7 for immediate breakout. Click to access these private picks>>
Mark Vickery
Senior Editor
Note: If you want an email notification each time Sheraz publishes a new article, pleaseclick here>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Top Research Reports for 9th November, 2016
Wednesday, November 9 2016
Today's Research Daily features new research reports on 16 major stocks, including Chevron (CVX - Free Report) , Glaxo (GSK - Free Report) and Aflac (AFL - Free Report) .
Chevron’s shares have gained more than 19% year-to-date. The analyst emphasizes that the company’s current oil and gas development project pipeline is among the best in the industry, boasting large, multi-year projects. Also, Chevron has been able to boost returns and remain competitive by embarking on aggressive cost reduction initiatives, exiting unprofitable markets and streamlining the organization.
Owing to these positives, the company has been able to report better-than-expected earnings in the third quarter. However, due to commodity price rout, Chevron’s upstream division has been able to extract less value for their products. (You can read the full research report on Chevron here.)
Glaxo’s shares have struggled recently. Glaxo’s third-quarter 2016 results were impressive with the company beating estimates on all fronts. The analyst likes Glaxo’s diversified base and presence in different geographical areas as well as its efforts to develop its pipeline.
The performance of new products as well as those acquired from Novartis is also encouraging. These should help support revenues and ease the impact of the loss of Advair sales. However, challenges remain in the form of increasing competition, genericization and pricing pressure, which will continue to impact the company’s performance. (You can read the full research report on Glaxo here.)
Aflac’s shares have increased by more than 8% year-to-date. Aflac’s third quarter earnings exceeded expectations and grew year over year. The analyst likes the way in which company is trying to differentiate itself from its rivals by paying claims in one day through a program named “One Day Pay.” Aflac’s strong capital position enables it to buy back shares and increase dividend payouts at regular intervals.
Efforts to increase agent productivity also will drive long-term growth. However, Aflac’s top line remains exposed to a challenging operating environment, primarily in Japan. (You can read the full research report on Aflac here.)
Other noteworthy reports we are featuring today include Analog Devices (ADI - Free Report) , Novo Nordisk (NVO - Free Report) and MGM Resorts (MGM - Free Report) .
Confidential: Best Trades from Zacks Research
Would you like to see a hand-picked "all-star" selection of investment ideas from the man who heads up Zacks' trading and investing services? Steve Reitmeister knows when key trades are about to be triggered and which of our experts has the hottest hand. He is now prepared to pass them along to you. From 220 Zacks Rank #1 Strong Buys, this Special tabs 7 for immediate breakout. Click to access these private picks>>
Mark Vickery
Senior Editor
Note: If you want an email notification each time Sheraz publishes a new article, please click here>>>